Aileen: Announcement on abnormal fluctuations in the company’s stock trading
Securities code: 002821 Securities abbreviation: Kai Laiying Announcement number: 2026-026
Asymchem Pharmaceutical Group (Tianjin) Co., Ltd.
Announcement on abnormal fluctuations in company stock trading
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete, and contains no false records, misleading statements or major omissions.
1. Abnormal fluctuations in stock trading
The cumulative deviation from the closing price increase of Asymchem Pharmaceutical Group (Tianjin) Co., Ltd. (hereinafter referred to as the "Company") stock (securities abbreviation: Asymchem, stock code: 002821) for three consecutive trading days from June 23, 2026 to June 25, 2026 exceeded 20%. According to the relevant regulations of the Shenzhen Stock Exchange, it is a case of abnormal fluctuations in stock trading.
2. Explanation of the company’s attention and verification of relevant situations
In response to the abnormal fluctuations in the company's stock trading, the company's board of directors has verified relevant matters and verified the company's controlling shareholders and actual controllers through correspondence inquiries. The relevant situation is now explained as follows:
There is no need to correct or supplement the information previously disclosed by the company;
The public media have not recently reported any undisclosed major information that may or has had a greater impact on the company’s stock trading price;
The company's production and operation conditions are normal, and there have been no major changes in the internal and external operating environment;
After inquiry, the company, controlling shareholders and actual controllers have no major matters that should be disclosed but have not been disclosed, nor are there any other major matters in the planning stage;
The company, controlling shareholders and actual controllers did not buy or sell the company’s stocks during the period of abnormal fluctuations in the company’s stock trading.
3. Whether there is an explanation of information that should be disclosed but has not been disclosed
The company's board of directors confirms that the company currently does not have any undisclosed matters that should be disclosed in accordance with the Shenzhen Stock Exchange's "Stock Listing Rules" and other relevant regulations, or any planning, negotiations, intentions, agreements, etc. related to the matter; the board of directors is also not informed that the company has undisclosed information that should be disclosed in accordance with the Shenzhen Stock Exchange's "Stock Listing Rules" and other relevant regulations, which has a greater impact on the company's stock trading price; there is no need to correct or supplement the information previously disclosed by the company.
4. Risk warning
After self-examination, the company did not violate the fair disclosure of information;
The company's board of directors solemnly reminds investors: the company's designated information disclosure media are "China Securities Journal", "Securities Times" and Juchao Information Network (http://www.cninfo.com.cn/). Information about the company is subject to the information published in the above designated media. The Company will strictly comply with the provisions and requirements of relevant laws and regulations, conscientiously perform its information disclosure obligations, and conduct information disclosure in a timely manner. Investors are kindly requested to invest rationally and pay attention to investment risks.
Announcement is hereby made.
Board of Directors of Asymchem Pharmaceutical Group (Tianjin) Co., Ltd.
June 26, 2026